The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood Pressure

• Publication date

  2016-04-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/08037051.2016.1139324PMID 27071504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct

  2018cited by this paper
• Patient Preferences for a Polypill for the Prevention of Cardiovascular Diseases

  2015cited by this paper
• Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes.

  2014cited by this paper
• HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION

  2014cited by this paper
• Family history of cardiovascular disease and influence on statin therapy persistence

  2014cited by this paper
• Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

  2014cited by this paper
• A polypill strategy to improve adherence: results from the FOCUS project.

  2014cited by this paper
• An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial

  2014cited by this paper
• to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project

  2014cited by this paper
• Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.

  2013cited by this paper
• The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDEHEART)

  2013cited by this paper
• Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences.

  2013cited by this paper
• 2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines

  2013cited by this paper
• ESH / ESC Guidelines for the management of arterial hypertension

  2013cited by this paper
• Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.

  2013cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

  2012cited by this paper
• Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.

  2011cited by this paper
• Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome

  2011cited by this paper
• Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach

  2011cited by this paper
• EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

  2010cited by this paper
• Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.

  2009cited by this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2008cited by this paper
• European cardiovascular disease statistics

  2008cited by this paper
• 2013 ESH/ESC Guidelines for the management of arterial hypertension

  2007cited by this paper
• Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.

  2006cited by this paper
• Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

  2006cited by this paper
• Counting the dead and what they died from: an assessment of the global status of cause of death data.

  2005cited by this paper
• Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

  2005cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice

  2004cited by this paper
• Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes

  2004influential reference
• Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

  2004influential reference
• Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

  2001cited by this paper
• Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

  1994cited by this paper

• Prognostic significance of suboptimal secondary prevention pharmacotherapy after acute coronary syndromes

  2020cites this paper
• Health Benefits of Anti-aging Drugs.

  2019cites this paper
• Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis

  2016influential citation